96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00048295
(ClinicalTrials.gov)
May 200229/10/2002Alicaforsen (ISIS 2302) in Patients With Active Crohn’s DiseaseISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s DiseaseCrohn's DiseaseDrug: AlicaforsenIsis PharmaceuticalsNULLActive, not recruiting12 YearsN/ABoth150Phase 3Belgium;Czech Republic;Germany;Italy;Poland;Spain
2NCT00048113
(ClinicalTrials.gov)
September 200124/10/2002Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's DiseaseCrohn's DiseaseDrug: AlicaforsenIsis PharmaceuticalsNULLCompleted12 YearsN/ABoth150Phase 3United States;Canada